

**Nonsteroidal MRAs:
Latest Evidence of Cardiorenal Protection in CKD and T2D**

Faculty:

Eugene E. Wright, Jr., MD, Jolanta Małyszko, MD, PhD, and María José Soler, MD, PhD

Presentation References

1. Bakris GL, Agarwal R, Anker SD, et al. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. *Am J Nephrol.* 2019;50(5):333-344.
2. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med.* 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845
3. Kerendia (finerenone). Package insert. Bayer Healthcare Pharmaceuticals, Inc.; 2021
4. Hubbard, D., Colantonio, L.D., Rosenson, R.S. et al. Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease. *Cardiovasc Diabetol.* 20, 58 (2021).
5. Pitt B, et al. FIGARO-DKD Trial. Presented at ESC 2021.
6. National Kidney Foundation.
https://www.kidney.org/kidneydisease/siemens_hcp_quickreference
7. Sumida K, Molnar MZ, Potukuchi PK, et al. Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease. *Clin J Am Soc Nephrol.* 2017;12(12):1941-1949.

Additional Resources

FIDELIO

<https://www.nejm.org/doi/full/10.1056/NEJMoa2025845>

<https://www.acc.org/latest-in-cardiology/clinical-trials/2020/11/11/21/54/fidelio-dkd>

FIGARO

<https://www.acc.org/latest-in-cardiology/clinical-trials/2021/08/25/23/58/figaro-dkd>

<https://www.nejm.org/doi/full/10.1056/NEJMoa2110956>

FIDELITY

<https://academic.oup.com/eurheartj/article/43/6/474/6433104>

https://www.acc.org/latest-in-cardiology/articles/2021/08/26/20/08/sat-1125am-figaro-dkd-esc-2021?utm_medium=social&utm_source=twitter_post&utm_campaign=esc21